Methylation status of NEUROG2 and NID2 improves the diagnosis of stage I NSCLC

Oncology Letters

Volumn 3, Issue 4, 2012, Pages 901-906

  Geng, Junfeng ^a   Sun, Jinfeng ^b   Lin, Qiang ^a   Gu, Jun ^b   Zhao, Yangxing ^b   Zhang, Hongyu ^b   Feng, Xu ^c   He, Yinghua ^b   Wang, Wei ^b   Zhou, Xiaoyu ^d   Yu, Jian ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c GUANGXI MEDICAL UNIVERSITY   (China)

^d SHANGHAI INSTITUTE OF PLANNED PARENTHOOD RESEARCH   (China)

Author keywords

DNA methylation; NEUROG2; NID2; Non small cell lung cancer; Stage I

Indexed keywords

APC PROTEIN; NEUROGENIN 2; NID2 PROTEIN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER TISSUE; CONTROLLED STUDY; DISEASE SEVERITY; DNA METHYLATION; EARLY DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR GENE;

EID: 84863172279     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.587     Document Type: Article

References (20)

1. Chen W, Zhang S and Zou X: Estimation and projection of lung cancer incidence and mortality in China. Zhongguo Fei Ai Za Zhi 13: 488-493, 2010 (In Chinese).
2. Luo J, Hendryx M and Ducatman A: Association between six environmental chemicals and lung cancer incidence in the United States. J Environ Public Health: Jul 10, 2011 (Epub ahead of print).
3. Molina JR, Yang P, Cassivi SD, et al: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83: 584-594, 2008.
4. Goldstraw P, Crowley J, Chansky K, et al: The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2: 706-714, 2007.
5. Besse B and Le Chevalier T: Adjuvant or induction cisplatin-based chemotherapy for operable lung cancer. Oncology (Williston Park) 23: 520-527, 2009.
6. Berger SL, Kouzarides T, Shiekhattar R and Shilatifard A: An operational definition of epigenetics. Genes Dev 23: 781-783, 2009.
7. Portela A and Esteller M: Epigenetic modifications and human disease. Nat Biotechnol 28: 1057-1068, 2010.
8. Feinberg AP: Cancer epigenetics is no Mickey Mouse. Cancer Cell 8: 267-268, 2005.
9. Lin Q, Geng J, Ma K, et al: RASSF1A, APC, ESR1, ABCB1 and HOXC9, but not p16INK4A, DAPK1, PTEN and MT1G genes were frequently methylated in the stage I non-small cell lung cancer in China. J Cancer Res Clin Oncol 135: 1675-1684, 2009.
10. Shames DS, Girard L, Gao B, et al: A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 3: e486, 2006.
11. Chung W, Kwabi-Addo B, Ittmann M, et al: Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. PLoS One 3: e2079, 2008.
12. Travis WD, Brambilla E, Müller-Hermelink HK. and Harris CC (eds): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press, Lyon, 2004.
13. Yu J, Ni M, Xu J, et al: Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis. BMC Cancer 2: 29, 2002.
14. Yu J, Zhang HY, Ma ZZ, et al: Methylation profiling of twenty four genes and the concordant methylation behaviours of nineteen genes that may contribute to hepatocellular carcinogenesis. Cell Res 13: 319-333, 2003.
15. Yu J, Zhu T, Wang Z, et al: A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res 13: 7296-7304, 2007.
16. Ludwig JA and Weinstein JN: Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5: 845-856, 2005.
17. Perrin FE, Boniface G, Serguera C, et al: Grafted human embryonic progenitors expressing neurogenin-2 stimulate axonal sprouting and improve motor recovery after severe spinal cord injury. PLoS One 5: e15914, 2010.
18. Kohfeldt E, Sasaki T, Göhring W and Timpl R: Nidogen-2: a new basement membrane protein with diverse binding properties. J Mol Biol 282: 99-109, 1998.
19. Ulazzi L, Sabbioni S, Miotto E, et al: Nidogen 1 and 2 gene promoters are aberrantly methylated in human gastrointestinal cancer. Mol Cancer 6: 17, 2007.
20. Kuk C, Gunawardana CG, Soosaipillai A, et al: Nidogen-2: a new serum biomarker for ovarian cancer. Clin Biochem 43: 355-361, 2010.